Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.

Cancer research - 15 May 2009

Steinkamp Mara P, O'Mahony Orla A, Brogley Michele, Rehman Haniya, Lapensee Elizabeth W, Dhanasekaran Saravana, Hofer Matthias D, Kuefer Rainer, Chinnaiyan Arul, Rubin Mark A, Pienta Kenneth J, Robins Diane M

Abstract excerpt

Mutations in the androgen receptor (AR) that enable activation by antiandrogens occur in hormone-refractory prostate cancer, suggesting that mutant ARs are selected by treatment. To validate this hypothesis, we compared AR variants in metastases obtained by rapid autopsy of patients treated with flutamide or bicalutamide, or by excision of lymph node metastases from hormone-naïve patients. AR mutations occurred...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Autopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cycloheximide

Share to Lymphatic Metastasis

Share to Nitriles

Share to Prostatic Neoplasms

Share to Receptors, Androgen

Share to RNA, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 19366804
DOI: 10.1158/0008-5472.CAN-08-3605
PMCID: PMC2765801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.PMID 19366804Read ↗

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.Semantic proximity Read ↗

Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.Semantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

Androgen receptor as a target in androgen-independent prostate cancer.Semantic proximity Read ↗

Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.Semantic proximity Read ↗

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.Semantic proximity Read ↗

Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.Semantic proximity Read ↗

Mutation of the androgen receptor causes oncogenic transformation of the prostate.Semantic proximity Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.